-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis, Eli Lilly Back Seawolf Therapeutics' $100 Million Series A Funding Round

MT Newswires·11/16/2026 06:36:58
Listen to the news
06:36 AM EST, 11/16/2026 (MT Newswires) -- Seawolf Therapeutics raised $100 million to advance its proprietary DNA delivery platform, the US-based biotechnology company said Monday. Participants in the series A funding round included founding investor Versant Ventures, Novartis' (NOVN.SW) Novartis Venture Fund, Eli Lilly (LLY.F, LLY.SW) and Alexandria Venture Investments. Trident is a redosable lipid nanoparticle-based DNA delivery system that can be used for mutant gene replacement and systemic biologics expression, among others.